LIPITOR TABLET 80 mg

国: シンガポール

言語: 英語

ソース: HSA (Health Sciences Authority)

有効成分:

ATORVASTATIN CALCIUM 86.80mg EQV ATORVASTATIN

から入手可能:

PFIZER PRIVATE LIMITED

ATCコード:

C10AA05

投薬量:

80 mg

医薬品形態:

TABLET, FILM COATED

投与経路:

ORAL

処方タイプ:

Prescription Only

製:

PFIZER PHARMACEUTICALS LIMITED (VEGA BAJA)

承認日:

2002-06-24

情報リーフレット

  
Page 1 of 20 

LIPITOR
®
 TABLETS 
ATORVASTATIN CALCIUM 

1.   TRADE NAME(S) OF THE MEDICINAL PRODUCT 

LIPITOR 

2.   QUALITATIVE AND QUANTITATIVE COMPOSITION 

Active Ingredient: atorvastatin. 

The tablets for oral administration contain atorvastatin calcium equivalent to 10,
20, 40, or 80 mg 
atorvastatin. 

3.   PHARMACEUTICAL FORM 

Tablets: 10 mg, 20 mg, 40 mg, 80 mg. 

4.   CLINICAL PARTICULARS 

4.1  THERAPEUTIC INDICATIONS 

Atorvastatin is indicated as an adjunct to diet for reduction
of elevated total cholesterol 
(total-C), LDL-cholesterol (LDL-C), apolipoprotein B, and
triglycerides in adults, 
adolescents and children aged 10 years or older with
primary hypercholesterolemia, 
heterozygous familial hypercholesterolemia, or combined
(mixed) hyperlipidemia 
(Fredrickson Types IIa and IIb), elevated serum triglyceride levels
(Fredrickson Type IV), 
and for patients with dysbetalipoproteinemia (Fredrickson Type
III) when response to diet 
and other non-pharmacological measures is inadequate. 

Atorvastatin also raises HDL-cholesterol and lowers the LDL/HDL and
total 
cholesterol/HDL ratios. 

Atorvastatin is also indicated to reduce total-C and LDL-C in
adults with homozygous 
familial hypercholesterolaemia as an adjunct to
other lipid-lowering treatments (e.g., LDL 
apheresis) or if such treatments are unavailable. 

_Prevention of Cardiovascular Disease_ 

Lipitor is indicated to reduce the risk of myocardial infarction
in adult hypertensive patients 
without clinically evident coronary heart disease,
but with at least three additional risk factors 
for coronary heart disease such as age  55 years, male sex,
smoking, left ventricular 
hypertrophy, other specified abnormalities on ECG,
microalbuminia or proteinuria, ratio of 
plasma total cholesterol to HDL-cholesterol  6, or premature
family history of coronary�